Introductory Remarks

摘要

MolDiag-Paca is an Integrated Project (IP) funded by the European Union in the 'Sixth Framework Programme'. The major aim of MolDiag-Paca is to make use of genetic profiles of pancreatic cancer and precursor lesions to improve the outcome of pancreatic cancer patients by providing novel and highly efficient molecular diagnostic tools for an early diagnosis. A consortium comprising 19 partners from Germany, Estonia, Italy, Spain, Sweden, and the UK started to work on MolDiag-Paca in August 2006. The partners from both academia and industry have a long-standing interest and expertise in pancreatic cancer biology, diagnosis and treatment. Some of the partners have been cooperating in previous European pancreatic cancer networks for more than a decade, and have been involved in high-throughput analyses of genomic, transcriptomic, proteomic and epigenetic profiles of pancreatic cancer or preneoplastic lesions.